BioWorld

Category Archives: NDA

He Said What?!?! Best Biotech Quotes of 2011

December 29, 2011 – 3:26 pm

As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…

Share
By Trista Morrison | Also posted in Accelerated approval, Antibody, Big pharma, Biologic, Biosimilar, Biotech conferences, Biotechnology, BLA, Cancer, Cardiovascular, Clinic, Clinical Trial, Collaboration, Complete Response Letter, Deals, Drug Approval, European Medicines Agency, FDA, Financing, Gene Therapy, Genomics, Healthcare reform, immunotherapy, IND, Investigational New Drug Application, IPO, New Drug Application, Orphan disease, Patents, PDUFA, Personalized medicine, Pharmaceutical, Phase I, Phase II, Phase III, Pipeline, Preclinical, Rare disease, Reimbursement, RNAi, siRNA, Stem cell, Supplemental new drug application, Uncategorized, venture captial | Tagged , , , | Comments (2)

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

December 28, 2011 – 6:11 pm
Share
By Jennifer Boggs | Also posted in Accelerated approval, Antibody, Big pharma, Biologic, Biosimilar, Biotech conferences, Biotechnology, BLA, Cancer, Cardiovascular, China, Clinic, Clinical Trial, Collaboration, Complete Response Letter, Deals, Drug Approval, European Medicines Agency, FDA, Financing, Gene Therapy, Genomics, Healthcare reform, immunotherapy, IND, Investigational New Drug Application, IPO, New Drug Application, Orphan disease, Patents, PDUFA, Personalized medicine, Pharmaceutical, Phase I, Phase II, Phase III, Pipeline, Preclinical, Rare disease, Reimbursement, RNAi, Uncategorized | Tagged , , , | Comments (1)

Race To Nowhere

May 19, 2011 – 6:42 pm

Racial profiling – long in the realm of bad law enforcement – was criticized as bad medicine, too, in a recent paper by scientists from the Mount Sinai School of Medicine.

Share
By Anette Breindl | Also posted in Big pharma, Biotechnology, Clinic, Clinical Trial, Investigational New Drug Application, New Drug Application, Orphan disease, Phase I, Phase II, Phase III, Pipeline, Supplemental new drug application | Tagged , , | Comments (0)